Subscribe
Share
Share
Embed
340B Insight provides members and supporters of 340B Health with timely updates and discussions about the 340B drug pricing program. The podcast helps listeners stay current with and learn more about 340B to help them serve their patients and communities and remain compliant. We publish new episodes twice a month, with news reports and in-depth interviews with leading health care practitioners, policy and legal experts, public policymakers, and our expert staff.
Intro [00:00:04]:
Welcome to 340B Insight from 340B Health.
David Glendinning [00:00:11]:
Hello from Washington, D.C. and welcome back to 340B
David Glendinning [00:00:15]:
Insight, the podcast about the 340B drug pricing program.
David Glendinning [00:00:19]:
I'm your host David Glendinning with 340B Health.
David Glendinning [00:00:23]:
Our guest today is 340B Health President and CEO
David Glendinning [00:00:26]:
Maureen Testoni. We speak with Maureen regularly
David Glendinning [00:00:30]:
and wanted to have her back on the show to give us a year end
David Glendinning [00:00:34]:
wrap up of all the developments in the 340B world.
David Glendinning [00:00:38]:
So here's that conversation. Today we
David Glendinning [00:00:41]:
are speaking again with 340B Health President and CEO
David Glendinning [00:00:45]:
Maureen Testoni. Maureen, thank you for making the time to
David Glendinning [00:00:49]:
be with us. And welcome back to 340B Insight.
Maureen Testoni [00:00:52]:
Thank you, David. I really appreciate the opportunity.
David Glendinning [00:00:54]:
It is December now, believe it or not, and you were
David Glendinning [00:00:58]:
last on the show in late September. What has been
David Glendinning [00:01:02]:
happening in 340B since then?
Maureen Testoni [00:01:04]:
I think the biggest issue in 340B has been a number
Maureen Testoni [00:01:07]:
of drug maker proposals to turn
Maureen Testoni [00:01:10]:
340B into a rebate. Other issues
Maureen Testoni [00:01:14]:
are that we're really focusing on are litigation
Maureen Testoni [00:01:17]:
around state contract pharmacy laws. There
Maureen Testoni [00:01:20]:
was also the first release of its
Maureen Testoni [00:01:24]:
kind by a state that had
Maureen Testoni [00:01:27]:
imposed certain reporting requirements on 340B hospitals.
Maureen Testoni [00:01:31]:
And that is something else that's new and I think
Maureen Testoni [00:01:35]:
important to understand.
David Glendinning [00:01:38]:
Let's start with the rebates. As I know that's been such a big deal
David Glendinning [00:01:41]:
for the 340B community and you just called it the number one concern at this
David Glendinning [00:01:45]:
point. Listeners of the show will know that Johnson and
David Glendinning [00:01:49]:
Johnson paused implementation of its rebate model
David Glendinning [00:01:52]:
after HRSA threatened strong enforcement actions. What
David Glendinning [00:01:56]:
is the latest on that issue?
Maureen Testoni [00:01:58]:
Johnson and Johnson has now sued hrsa. They're essentially saying that
Maureen Testoni [00:02:01]:
HRSA does not have the authority to block a rebate model.
Maureen Testoni [00:02:05]:
And since then, we're also seeing three other
Maureen Testoni [00:02:08]:
manufacturers come out saying that they
Maureen Testoni [00:02:12]:
want to do a rebate proposal. Bristol Myers,
Maureen Testoni [00:02:16]:
Squibb and Lilly have also sued
Maureen Testoni [00:02:19]:
HRSA, saying that they don't have authority to stop
Maureen Testoni [00:02:23]:
a rebate model. And both manufacturers want to impose a rebate
Maureen Testoni [00:02:27]:
model. And then Sanofi announced that it
Maureen Testoni [00:02:30]:
was going to go forward and impose a rebate model effective
Maureen Testoni [00:02:35]:
January 6th. So we'll see if
Maureen Testoni [00:02:38]:
that goes forward there. But that is something that is obviously very concerning
Maureen Testoni [00:02:42]:
because of the short date.
David Glendinning [00:02:46]:
And let's talk about some of the concerns that the
David Glendinning [00:02:50]:
340B community has. What are some of those main concerns about
David Glendinning [00:02:53]:
340B rebates when it comes to hospitals?
Maureen Testoni [00:02:57]:
Well, sticking with Sanofi, you know, they were,
Maureen Testoni [00:03:01]:
Sanofi was very explicit about
Maureen Testoni [00:03:04]:
the rules that they're gonna oppose before they would
Maureen Testoni [00:03:07]:
approve a 340B rebate for a drug. And it's
Maureen Testoni [00:03:11]:
very concerning because what Sanofi is saying is that we're gonna
Maureen Testoni [00:03:15]:
impose our own as to which
Maureen Testoni [00:03:18]:
individuals 340B hospitals can deem to
Maureen Testoni [00:03:22]:
be to qualify for 340B. And the rules that they're
Maureen Testoni [00:03:25]:
imposing are clearly intended to reduce
Maureen Testoni [00:03:29]:
the number of patients that hospitals can consider to be patients
Maureen Testoni [00:03:33]:
for 340B purposes. So this would essentially reduce the
Maureen Testoni [00:03:37]:
number of drugs that the company would have to offer a 340b
Maureen Testoni [00:03:41]:
discount on. Some of the things that they are
Maureen Testoni [00:03:44]:
doing is they are requiring
Maureen Testoni [00:03:47]:
that patients have been seen at the covered entity
Maureen Testoni [00:03:51]:
within two years. That is a rule that does not
Maureen Testoni [00:03:55]:
exist anywhere under HRSA's compliance
Maureen Testoni [00:03:58]:
policies. They are requiring that the
Maureen Testoni [00:04:02]:
prescription be directly linked to the type
Maureen Testoni [00:04:06]:
of medical care, to an actual service that the individual has
Maureen Testoni [00:04:10]:
received at the covered entity. And yet we
Maureen Testoni [00:04:14]:
all know that under 340 rules
Maureen Testoni [00:04:18]:
there can be follow up care, there can be referrals, referrals.
Maureen Testoni [00:04:21]:
HRSA does not make that tight a limit as to when
Maureen Testoni [00:04:24]:
340B can be used. They have
Maureen Testoni [00:04:28]:
rules around hospitals only using
Maureen Testoni [00:04:32]:
prescribers that are employed by the hospital or
Maureen Testoni [00:04:37]:
have some other type of affiliation which is really not spelled out what
Maureen Testoni [00:04:40]:
that affiliation would need to look like. They're requiring various
Maureen Testoni [00:04:44]:
types of patient encounter data to be able to make some of
Maureen Testoni [00:04:48]:
these determinations. And that is just
Maureen Testoni [00:04:51]:
very concerning that they would try to impose
Maureen Testoni [00:04:55]:
their own rules like this under a rebate program.
Maureen Testoni [00:04:59]:
And I think that's a big concern that hospitals have.
David Glendinning [00:05:02]:
And I will mention that there's no public response to the
David Glendinning [00:05:06]:
Sanofi plan from HRSA yet and no lawsuit from the company though, that
David Glendinning [00:05:09]:
says of when we are speaking today. We know things can change quickly in
David Glendinning [00:05:13]:
this area. So that covers Sanofi. What do we know at this point
David Glendinning [00:05:17]:
about the other rebate models that drug makers
David Glendinning [00:05:21]:
are pushing?
Maureen Testoni [00:05:22]:
We don't have a lot of details really on the other rebate models.
Maureen Testoni [00:05:25]:
We know that Johnson and Johnson plan to use the same
Maureen Testoni [00:05:29]:
vendor, Beacon, for processing its
Maureen Testoni [00:05:32]:
rebates. So they do have information on the types of claims,
Maureen Testoni [00:05:36]:
some of the claims data that they're looking for, but they don't really
Maureen Testoni [00:05:40]:
provide all the details as to how they're going
Maureen Testoni [00:05:44]:
to use that information to determine whether to approve
Maureen Testoni [00:05:47]:
a claim. They just say we're going to get this data
Maureen Testoni [00:05:51]:
and we will then determine whether to approve. But they're
Maureen Testoni [00:05:55]:
not really saying what you would have to show for sure
Maureen Testoni [00:06:00]:
to make sure that your claim would be approved. That's a distinction
Maureen Testoni [00:06:03]:
with Sanofi going into a lot more detail about the new rules
Maureen Testoni [00:06:07]:
that they are imposing. Similarly with
Maureen Testoni [00:06:11]:
Lilly and with Bristol Myers Scopes. We don't
Maureen Testoni [00:06:14]:
know exactly what the rules are that they are proposing.
Maureen Testoni [00:06:18]:
And that is obviously concerning for hospitals because now
Maureen Testoni [00:06:22]:
if rebates were to go forward, it's all in the hands of the
Maureen Testoni [00:06:25]:
manufacturers as to whether and when you would receive the
Maureen Testoni [00:06:29]:
340B discount that you know you are supposed to be getting that they are obligated
Maureen Testoni [00:06:33]:
to provide you under the 340B statute.
David Glendinning [00:06:35]:
Why are drug companies saying they need to impose
David Glendinning [00:06:39]:
rebates on 340B hospitals? What reasons are they giving in all of
David Glendinning [00:06:43]:
these notices and lawsuits they've been filing?
Maureen Testoni [00:06:45]:
Manufacturers have been claiming that 340B has grown, you
Maureen Testoni [00:06:49]:
know, beyond what it is supposed to grow. So they are concerned
Maureen Testoni [00:06:53]:
about the fact that a high number of their drugs are being subject to
Maureen Testoni [00:06:57]:
340B discounts than there were in 1992 when
Maureen Testoni [00:07:00]:
340B was enacted. But the truth is
Maureen Testoni [00:07:04]:
healthcare has moved from the inpatient setting in the hospital to the
Maureen Testoni [00:07:07]:
outpatient setting. So many more drugs are available in the
Maureen Testoni [00:07:11]:
outpatient setting than there were in 1992. And, you
Maureen Testoni [00:07:15]:
know, we have, you know, people aren't necessarily even getting certain heart
Maureen Testoni [00:07:18]:
surgeries anymore because they can rely on certain specialty drugs
Maureen Testoni [00:07:22]:
to address that. So it's not a surprise they are also claiming
Maureen Testoni [00:07:26]:
that three 340B covered entities are not always following the rules
Maureen Testoni [00:07:30]:
around 340B and that they believe, you know,
Maureen Testoni [00:07:33]:
HRSA isn't doing a good job with that.
Maureen Testoni [00:07:37]:
And that's, you know, you can see this with, especially with the types of rules
Maureen Testoni [00:07:40]:
that Sanofi is trying to put into place around, you know,
Maureen Testoni [00:07:44]:
does the individual patient really qualify for
Maureen Testoni [00:07:48]:
340B? But the truth is, you, the
Maureen Testoni [00:07:51]:
Sanofi does not going to be able to figure that out. You know, this is
Maureen Testoni [00:07:55]:
something you have to look at medical charts. When HRSA goes in and audits
Maureen Testoni [00:07:59]:
covered entities, they are looking at the
Maureen Testoni [00:08:02]:
charts, at the patient charts to make that determination as
Maureen Testoni [00:08:06]:
to whether the hospitals are appropriately using
Maureen Testoni [00:08:09]:
340B for the right kinds of patients. And in recent
Maureen Testoni [00:08:13]:
years, we're seeing findings in that area against
Maureen Testoni [00:08:17]:
hospitals to be very, very low. So there is just no
Maureen Testoni [00:08:20]:
evidence of widespread abuse by
Maureen Testoni [00:08:24]:
hospitals in the area of whether or not patients really
Maureen Testoni [00:08:28]:
qualify for 340 B. And another issue that they bring up
Maureen Testoni [00:08:31]:
is something that's called a duplicate discount. It's a little
Maureen Testoni [00:08:35]:
confusing. It means that if an entity
Maureen Testoni [00:08:39]:
buys a drug at the 340b price, then the Medicaid
Maureen Testoni [00:08:42]:
agency should not be requesting a
Maureen Testoni [00:08:46]:
rebate from the manufacturer for that drug. And when
Maureen Testoni [00:08:50]:
you look at the findings from HRSA audits, there is
Maureen Testoni [00:08:54]:
nothing in any of those findings to suggest that there's widespread
Maureen Testoni [00:08:58]:
duplicate discounts going on. Because the fact is, HRSA
Maureen Testoni [00:09:02]:
does not check to see whether or not a
Maureen Testoni [00:09:06]:
state actually sought a rebate and whether or not
Maureen Testoni [00:09:09]:
the manufacturer actually paid it for a 340B drug. The
Maureen Testoni [00:09:13]:
only thing that HRSA does when they go into their
Maureen Testoni [00:09:17]:
audit is identify whether the hospital
Maureen Testoni [00:09:21]:
complied with duplicate discount requirements. And those
Maureen Testoni [00:09:24]:
requirements are that the hospital has to put his billing number up on
Maureen Testoni [00:09:28]:
HRSA's website. And that way states can use that billing number to
Maureen Testoni [00:09:32]:
make, to exclude any of the drug claims that
Maureen Testoni [00:09:36]:
are for Medicaid patients. So hospitals,
Maureen Testoni [00:09:40]:
you know, if they transpose, you know, a couple of numbers in
Maureen Testoni [00:09:44]:
their, when they put it up on the website, they'll get a finding that says
Maureen Testoni [00:09:46]:
duplicate discounts. And in fact, many hospitals are able
Maureen Testoni [00:09:50]:
to get the duplicate discount finding change to, you
Maureen Testoni [00:09:54]:
know, a web site error finding because they're able to get their
Maureen Testoni [00:09:57]:
Medicaid agency to say, no, we don't even use HRSA's website. We have our
Maureen Testoni [00:10:01]:
own process for identifying 340B claims,
Maureen Testoni [00:10:05]:
and we can confirm we have not made any requests to the manufacturers for
Maureen Testoni [00:10:08]:
rebates on this entity's claims. So when we're seeing
Maureen Testoni [00:10:12]:
findings made by the government on duplicate discounts, it's really important to understand
Maureen Testoni [00:10:16]:
that does not in any way, shape or form mean that a duplicate discount actually
Maureen Testoni [00:10:20]:
occurred. And we have not seen real data
Maureen Testoni [00:10:23]:
produced by these manufacturers to demonstrate that,
Maureen Testoni [00:10:27]:
that this is actually a serious issue.
David Glendinning [00:10:30]:
Our listeners will be eager to know where this whole
David Glendinning [00:10:34]:
rebate debate leads for them. So what is
David Glendinning [00:10:37]:
340B Health doing to advocate against these rebates?
Maureen Testoni [00:10:41]:
One, now that it's in the federal courts, we will again be
Maureen Testoni [00:10:45]:
very involved with the litigation. In previous litigation
Maureen Testoni [00:10:49]:
that has been filed by manufacturers against the government,
Maureen Testoni [00:10:52]:
we have always submitted amicus briefs,
Maureen Testoni [00:10:56]:
sometimes on our own, sometimes we work with other associations. So we
Maureen Testoni [00:11:00]:
are currently in discussions with our legal counsel to determine the best
Maureen Testoni [00:11:04]:
way to interact in these cases, whether
Maureen Testoni [00:11:07]:
it is by actually intervening, which would, if we got permission to
Maureen Testoni [00:11:11]:
intervene, that would allow us to make arguments directly
Maureen Testoni [00:11:15]:
to the judge. So it gives us a little bit more of a presence
Maureen Testoni [00:11:19]:
than an amicus. However, I will mention this is
Maureen Testoni [00:11:22]:
likely to take a While this is unlikely to be a fast moving
Maureen Testoni [00:11:26]:
lawsuit, so there is, you know, there still is some time
Maureen Testoni [00:11:30]:
before the court is really going to require any briefing on this
Maureen Testoni [00:11:34]:
case. You know, I will also mention that the ira,
Maureen Testoni [00:11:38]:
the legislation about that includes provisions to allow
Maureen Testoni [00:11:41]:
Medicare to negotiate lower prices for drug is going
Maureen Testoni [00:11:45]:
to be implemented in, you know, in the coming year.
Maureen Testoni [00:11:49]:
And manufacturers are going to be submitting within a few months their
Maureen Testoni [00:11:52]:
plans for implementing how they're
Maureen Testoni [00:11:56]:
going to make the Medicare prices available. And
Maureen Testoni [00:12:00]:
it's been controversial as to how 340
Maureen Testoni [00:12:04]:
is going to fit into that. Covered entities
Maureen Testoni [00:12:08]:
are entitled to the 340b price regardless of what the
Maureen Testoni [00:12:11]:
Medicare price is. But the process that the government
Maureen Testoni [00:12:15]:
is using to implement it does conflict with
Maureen Testoni [00:12:18]:
340B in some ways. It is absolutely
Maureen Testoni [00:12:22]:
doable to do what the government is proposing. But the
Maureen Testoni [00:12:25]:
manufacturers believe that it is having a
Maureen Testoni [00:12:29]:
rebate program would make it easier for them to
Maureen Testoni [00:12:32]:
comply with the, with the government's, you
Maureen Testoni [00:12:36]:
know, process. So I think it's important that we
Maureen Testoni [00:12:39]:
have a lot of advocacy going on about the fact this is not
Maureen Testoni [00:12:43]:
needed. Rebates are not needed for the IRA as
Maureen Testoni [00:12:47]:
well. I wrote about this in a, in a Wall Street Journal essay
Maureen Testoni [00:12:51]:
recently. The IRA was never intended to transform 340B
Maureen Testoni [00:12:55]:
into a rebate system. The government has refused to require
Maureen Testoni [00:12:58]:
340B rebates either for the Medicare
Maureen Testoni [00:13:02]:
program, the drugs that are subject to the negotiation, or otherwise
Maureen Testoni [00:13:06]:
for 340B drugs. And drug makers absolutely
Maureen Testoni [00:13:10]:
have other avenues to comply with the IRA
Maureen Testoni [00:13:13]:
and 340B which the Centers for
Maureen Testoni [00:13:17]:
Medicare and Medicaid Services is saying that they are
Maureen Testoni [00:13:20]:
exploring as well. So it's important that
Maureen Testoni [00:13:24]:
we are, you know, advocating against rebates for 340B
Maureen Testoni [00:13:28]:
but also in the context of the Medicare
Maureen Testoni [00:13:31]:
negotiation scheme.
David Glendinning [00:13:33]:
At the top of the show you mentioned the contract
David Glendinning [00:13:36]:
pharmacy litigation over state laws. What is the
David Glendinning [00:13:40]:
latest status on those?
Maureen Testoni [00:13:42]:
So far we have seen a number of lawsuits from
Maureen Testoni [00:13:45]:
manufacturers and from their association
Maureen Testoni [00:13:48]:
pharmacy. And a lot of those are we're arguing
Maureen Testoni [00:13:52]:
that, you know, the states just do not have the authority to make
Maureen Testoni [00:13:56]:
any rules around 340 because 340B is a federal law. And so
Maureen Testoni [00:13:59]:
far they have lost those. So that has been
Maureen Testoni [00:14:03]:
great. However, there are some manufacturers are making
Maureen Testoni [00:14:06]:
new arguments around very technical
Maureen Testoni [00:14:10]:
issues about whether the providers retain
Maureen Testoni [00:14:13]:
title when the drugs are transferred to the contract pharmacy and some
Maureen Testoni [00:14:17]:
other issues. We are very involved in these cases.
Maureen Testoni [00:14:21]:
Cases. We do amicus briefs for all of these lawsuits along
Maureen Testoni [00:14:24]:
with a couple of others of the hospital associations and
Maureen Testoni [00:14:28]:
State associations. But we are also working
Maureen Testoni [00:14:31]:
closely with some of the attorneys that are working on some of
Maureen Testoni [00:14:35]:
these cases to assist with
Maureen Testoni [00:14:39]:
the more technical analysis about this. Whether there is
Maureen Testoni [00:14:43]:
any merit to some of these arguments
Maureen Testoni [00:14:47]:
that the manufacturers are making, I do not believe there is. But
Maureen Testoni [00:14:50]:
that is the case that we are really building up right now and that I
Maureen Testoni [00:14:54]:
expect to be the big issue in the coming year.
David Glendinning [00:14:57]:
You also said there's a new 340B report out,
David Glendinning [00:15:00]:
and our regular listeners will know that is coming from
David Glendinning [00:15:04]:
Minnesota, the land of 10,000 lakes. What does
David Glendinning [00:15:07]:
that report say?
Maureen Testoni [00:15:10]:
So this Minnesota report,
Maureen Testoni [00:15:15]:
it comes out of legislation that was
Maureen Testoni [00:15:19]:
passed in 2023 that
Maureen Testoni [00:15:22]:
requires covered any
Maureen Testoni [00:15:25]:
to submit certain information
Maureen Testoni [00:15:29]:
to the state. And one of the things that they
Maureen Testoni [00:15:33]:
required is that covered entities report the
Maureen Testoni [00:15:37]:
prices, you know, they're spending on 340B drugs
Maureen Testoni [00:15:40]:
and then how much they received from insurers, you know,
Maureen Testoni [00:15:44]:
in payment for those drugs. And that number, the number that they
Maureen Testoni [00:15:48]:
released was 630 million.
Maureen Testoni [00:15:52]:
Now, that is a calculation that we are
Maureen Testoni [00:15:55]:
really take issue with because it really overstates
Maureen Testoni [00:15:59]:
the value of 340B. 630 million is not the value
Maureen Testoni [00:16:03]:
of 340B. For the hospitals in Minnesota,
Maureen Testoni [00:16:07]:
the value is going to be lower than that. And that's because all that
Maureen Testoni [00:16:11]:
340B does is it gives a discount on the
Maureen Testoni [00:16:14]:
drug. But hospitals that aren't in 340B don't
Maureen Testoni [00:16:18]:
buy the drug at the sticker price. It's called wholesale acquisition cost,
Maureen Testoni [00:16:22]:
which is like the car sticker price. Nobody buys it at that. And so if
Maureen Testoni [00:16:25]:
they weren't in 340B, they would still be getting discounts on drugs by
Maureen Testoni [00:16:29]:
purchasing through their group purchasing organization. So the
Maureen Testoni [00:16:33]:
630 millions is a number that may apply.
Maureen Testoni [00:16:37]:
If everybody was purchasing their drugs at WAC and the
Maureen Testoni [00:16:41]:
only people that got a discount was 340B.
Maureen Testoni [00:16:44]:
So what you really want to do, if you were trying to see what the
Maureen Testoni [00:16:47]:
benefit of 340B is, is you would compare the GPO
Maureen Testoni [00:16:51]:
prices that hospitals have against what they're paying for 340B. So if
Maureen Testoni [00:16:55]:
the 340B price is 80, the GPO price is
Maureen Testoni [00:16:58]:
100, and the sticker price, the WACC price is
Maureen Testoni [00:17:01]:
200, then the real difference isn't going to be between
Maureen Testoni [00:17:05]:
that $80 and the 200. It's going to be between the $80
Maureen Testoni [00:17:09]:
for 340B and the 100 for the GPO. But even looking at
Maureen Testoni [00:17:13]:
that 630 number, it's important to understand
Maureen Testoni [00:17:17]:
what that number means in terms of how much is spent on
Maureen Testoni [00:17:21]:
patient care by Minnesota hospitals overall? And that
Maureen Testoni [00:17:24]:
is $15 billion on patient care
Maureen Testoni [00:17:28]:
last year. And about $770 million
Maureen Testoni [00:17:32]:
was spent on uncompensated, unreimbursed care. So
Maureen Testoni [00:17:36]:
that is care where the hospital received no
Maureen Testoni [00:17:40]:
compensation. You know, people that just did not have insurance or
Maureen Testoni [00:17:44]:
care where they received, you know, less than their
Maureen Testoni [00:17:47]:
costs, such as, you know, Medicaid, which
Maureen Testoni [00:17:50]:
notoriously pays much less than the cost. And then if you
Maureen Testoni [00:17:54]:
were to add to that number the underpayment that hospitals
Maureen Testoni [00:17:58]:
receive from Medicare, I personally believe that number would
Maureen Testoni [00:18:01]:
be closer to a billion dollars. And so without
Maureen Testoni [00:18:05]:
340B, it'd be very difficult for hospitals maintain that
Maureen Testoni [00:18:08]:
level of.
David Glendinning [00:18:09]:
Care if it's the end of the year. We here at 340B Health
David Glendinning [00:18:13]:
are preparing for the upcoming 340B Coalition Winter Conference.
David Glendinning [00:18:17]:
What are you most looking forward to for that meeting?
Maureen Testoni [00:18:19]:
I really love our conferences. It's just such a Great so
Maureen Testoni [00:18:23]:
many 340B minds in one place is just is
Maureen Testoni [00:18:27]:
really fun for me. And you know, this year our conference will be in San
Maureen Testoni [00:18:30]:
Diego. It'll be in February 24th to the 26th.
Maureen Testoni [00:18:34]:
I really encourage everybody who is really interested in
Maureen Testoni [00:18:37]:
340B to attend. We do a lot of
Maureen Testoni [00:18:41]:
sessions on compliance issues, including the
Maureen Testoni [00:18:45]:
inflation Reduction act, the Medicare negotiation policy that I
Maureen Testoni [00:18:49]:
talked about earlier Sessions on optimizing 340B on how
Maureen Testoni [00:18:52]:
to stay compliant. On 340B, we will have sessions to
Maureen Testoni [00:18:56]:
sort of what to expect in Washington with the new administration
Maureen Testoni [00:19:00]:
and the new Congress. And our featured speaker will be a
Maureen Testoni [00:19:03]:
Harvard professor that's going to be discussing the future of
Maureen Testoni [00:19:07]:
healthcare economics. So it's a great way to network with other
Maureen Testoni [00:19:10]:
340B people. It's a great way to learn about,
Maureen Testoni [00:19:14]:
learn new strategies that your peers may be using around
Maureen Testoni [00:19:18]:
340B. You know, sharing best practices, learning new ideas,
Maureen Testoni [00:19:22]:
talking about 340B advocacy. Early Bird registration
Maureen Testoni [00:19:25]:
is going on right now and it's going to end December 20th.
Maureen Testoni [00:19:29]:
So I really encourage people to sign up before then so you can
Maureen Testoni [00:19:33]:
secure your discounted rate.
David Glendinning [00:19:34]:
And we will be sure to put that link and a few other links of
David Glendinning [00:19:37]:
interest in the show notes so our listeners don't need to venture far to find
David Glendinning [00:19:41]:
them. Maureen, thank you for taking the time during the
David Glendinning [00:19:44]:
pre holiday rush to be with us today. We all appreciate it.
Maureen Testoni [00:19:48]:
Well, thank you so much for having me. I really appreciate it. Dave.
David Glendinning [00:19:50]:
We thank Maureen Testoni again for being with us today and
David Glendinning [00:19:54]:
all year long. And we thank you, our loyal listeners
David Glendinning [00:19:58]:
for joining us during this season of 340B Insight. This
David Glendinning [00:20:02]:
is our last episode of 2024 and we will be taking a
David Glendinning [00:20:05]:
short break while we prepare for another full season of episodes
David Glendinning [00:20:09]:
in 2025. Please keep those ideas coming
David Glendinning [00:20:13]:
for episodes and guests. You can always email us at
David Glendinning [00:20:17]:
podcast340bhealth.org have
David Glendinning [00:20:20]:
a joyous, peaceful holiday season and a happy, healthy
David Glendinning [00:20:24]:
new Year. We will be back in January. In the meantime, as
David Glendinning [00:20:27]:
always, thanks for listening and be well.
Outro [00:20:34]:
Thanks for listening to 340B Insight. Subscribe and rate
Outro [00:20:38]:
us on Apple Podcasts, Google Play, Spotify, or wherever
Outro [00:20:42]:
you listen to podcasts. For more information, visit our
Outro [00:20:46]:
website@340bpodcast.org you can also
Outro [00:20:49]:
follow us on Twitter behealth and submit a question or
Outro [00:20:53]:
idea to the show by emailing us at
Outro [00:20:56]:
podcast@340bhealth.org.